Malignant Solid Tumour Clinical Trial
Official title:
A Phase I Clinical Trial of Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer.
This is a multi-center, open-label non-randomized dose-escalation trial of vorinostat given in combination with vinorelbine. Cohorts will be treated with a fixed dose of vinorelbine (25mg/m²/week continuously, representing the schedule that has been approved). Patients eligible will be enrolled into a standard 3+3 design with a starting dose of vorinostat at 200 mg po qd 7/21 (weekly schedule). Then, further dose levels will be explored. Toxicity of the schedule will be assessed during the first cycle. Patients may receive up to 6 cycles of study medication. Blood samples will be collected at specified time points to assess pharmacokinetic endpoints.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01721148 -
A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours
|
Phase 1 | |
| Completed |
NCT00551096 -
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01023737 -
Hydroxychloroquine + Vorinostat in Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT01435096 -
BN80927 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
| Completed |
NCT01951846 -
To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
|
Phase 1 | |
| Completed |
NCT01325558 -
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT01554371 -
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01309490 -
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT01286896 -
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00635791 -
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT01376505 -
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00388427 -
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01611857 -
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
|
Phase 1/Phase 2 | |
| Completed |
NCT02853903 -
Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors
|
Phase 2 | |
| Completed |
NCT02843204 -
Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT01618136 -
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02786628 -
Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
|
||
| Completed |
NCT01184807 -
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00969410 -
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
|
Phase 1 | |
| Completed |
NCT02857920 -
Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors
|
Phase 1/Phase 2 |